Technologies

A joint CU-National Jewish research team led by Kathryn Haskins and John Kappler has identified a series of peptides in chromogranin A (ChgA) that may be the antigen(s) for a group of highly diabetogenic CD4 T cell clones, including the well-studied BDC-2.5 clone. In particular. a natural cleavage product of ChgA appears to be the primary immunogenic peptide. The research team has also developed antibodies against this peptide. The peptides and the antibodies can be used as diagnostic tools for identifying T1D patients, and they may also provide therapeutic and prophylactic treatments for type I diabetes.